Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Correction: Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma-experience of the BriTROC consortium.

Goranova T, Ennis D, Piskorz AM, Macintyre G, Lewsley LA, Stobo J, Wilson C, Kay D, Glasspool RM, Lockley M, Brockbank E, Montes A, Walther A, Sundar S, Edmondson R, Hall GD, Clamp A, Gourley C, Hall M, Fotopoulou C, Gabra H, Freeman S, Moore L, Jimenez-Linan M, Paul J, Brenton JD, McNeish IA; BriTROC investigators.

Br J Cancer. 2019 Mar 13. doi: 10.1038/s41416-019-0433-6. [Epub ahead of print]

PMID:
30862952
2.

Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk.

Yang Y, Wu L, Shu X, Lu Y, Shu XO, Cai Q, Beeghly-Fadiel A, Li B, Ye F, Berchuck A, Anton-Culver H, Banerjee S, Benitez J, Bjørge L, Brenton JD, Butzow R, Campbell IG, Chang-Claude J, Chen K, Cook LS, Cramer DW, deFazio A, Dennis J, Doherty JA, Dörk T, Eccles DM, Edwards DV, Fasching PA, Fortner RT, Gayther SA, Giles GG, Glasspool RM, Goode EL, Goodman MT, Gronwald J, Harris HR, Heitz F, Hildebrandt MA, Høgdall E, Høgdall CK, Huntsman DG, Kar SP, Karlan BY, Kelemen LE, Kiemeney LA, Kjaer SK, Koushik A, Lambrechts D, Le ND, Levine DA, Massuger LF, Matsuo K, May T, McNeish IA, Menon U, Modugno F, Monteiro AN, Moorman PG, Moysich KB, Ness RB, Nevanlinna H, Olsson H, Onland-Moret NC, Park SK, Paul J, Pearce CL, Pejovic T, Phelan CM, Pike MC, Ramus SJ, Riboli E, Rodriguez-Antona C, Romieu I, Sandler DP, Schildkraut JM, Setiawan VW, Shan K, Siddiqui N, Sieh W, Stampfer MJ, Sutphen R, Swerdlow AJ, Szafron LM, Teo SH, Tworoger SS, Tyrer JP, Webb PM, Wentzensen N, White E, Willett WC, Wolk A, Woo YL, Wu AH, Yan L, Yannoukakos D, Chenevix-Trench G, Sellers TA, Pharoah PDP, Zheng W, Long J.

Cancer Res. 2019 Feb 1;79(3):505-517. doi: 10.1158/0008-5472.CAN-18-2726. Epub 2018 Dec 17.

PMID:
30559148
3.

Copy number signatures and mutational processes in ovarian carcinoma.

Macintyre G, Goranova TE, De Silva D, Ennis D, Piskorz AM, Eldridge M, Sie D, Lewsley LA, Hanif A, Wilson C, Dowson S, Glasspool RM, Lockley M, Brockbank E, Montes A, Walther A, Sundar S, Edmondson R, Hall GD, Clamp A, Gourley C, Hall M, Fotopoulou C, Gabra H, Paul J, Supernat A, Millan D, Hoyle A, Bryson G, Nourse C, Mincarelli L, Sanchez LN, Ylstra B, Jimenez-Linan M, Moore L, Hofmann O, Markowetz F, McNeish IA, Brenton JD.

Nat Genet. 2018 Sep;50(9):1262-1270. doi: 10.1038/s41588-018-0179-8. Epub 2018 Aug 13.

4.

Routine germline BRCA1 and BRCA2 testing in patients with ovarian carcinoma: analysis of the Scottish real-life experience.

Rust K, Spiliopoulou P, Tang CY, Bell C, Stirling D, Phang T, Davidson R, Mackean M, Nussey F, Glasspool RM, Reed NS, Sadozye A, Porteous M, McGoldrick T, Ferguson M, Miedzybrodzka Z, McNeish IA, Gourley C.

BJOG. 2018 Oct;125(11):1451-1458. doi: 10.1111/1471-0528.15171. Epub 2018 May 10.

5.

The Driver Mutational Landscape of Ovarian Squamous Cell Carcinomas Arising in Mature Cystic Teratoma.

Cooke SL, Ennis D, Evers L, Dowson S, Chan MY, Paul J, Hirschowitz L, Glasspool RM, Singh N, Bell S, Day E, Kochman A, Wilkinson N, Beer P, Martin S, Millan D, Biankin AV, McNeish IA; Scottish Genomes Partnership.

Clin Cancer Res. 2017 Dec 15;23(24):7633-7640. doi: 10.1158/1078-0432.CCR-17-1789. Epub 2017 Sep 27.

6.

Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma-experience of the BriTROC consortium.

Goranova T, Ennis D, Piskorz AM, Macintyre G, Lewsley LA, Stobo J, Wilson C, Kay D, Glasspool RM, Lockley M, Brockbank E, Montes A, Walther A, Sundar S, Edmondson R, Hall GD, Clamp A, Gourley C, Hall M, Fotopoulou C, Gabra H, Freeman S, Moore L, Jimenez-Linan M, Paul J, Brenton JD, McNeish IA.

Br J Cancer. 2017 May 9;116(10):1294-1301. doi: 10.1038/bjc.2017.86. Epub 2017 Mar 30. Erratum in: Br J Cancer. 2019 Mar 13;:.

7.

No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival.

Sucheston-Campbell LE, Cannioto R, Clay AI, Etter JL, Eng KH, Liu S, Battaglia S, Hu Q, Szender JB, Minlikeeva A, Joseph JM, Mayor P, Abrams SI, Segal BH, Wallace PK, Soh KT, Zsiros E, Anton-Culver H, Bandera EV, Beckmann MW, Berchuck A, Bjorge L, Bruegl A, Campbell IG, Campbell SP, Chenevix-Trench G, Cramer DW, Dansonka-Mieszkowska A, Dao F, Diergaarde B, Doerk T, Doherty JA, du Bois A, Eccles D, Engelholm SA, Fasching PA, Gayther SA, Gentry-Maharaj A, Glasspool RM, Goodman MT, Gronwald J, Harter P, Hein A, Heitz F, Hillemmanns P, Høgdall C, Høgdall EV, Huzarski T, Jensen A, Johnatty SE, Jung A, Karlan BY, Klapdor R, Kluz T, Konopka B, Kjær SK, Kupryjanczyk J, Lambrechts D, Lester J, Lubiński J, Levine DA, Lundvall L, McGuire V, McNeish IA, Menon U, Modugno F, Ness RB, Orsulic S, Paul J, Pearce CL, Pejovic T, Pharoah P, Ramus SJ, Rothstein J, Rossing MA, Rübner M, Schildkraut JM, Schmalfeldt B, Schwaab I, Siddiqui N, Sieh W, Sobiczewski P, Song H, Terry KL, Van Nieuwenhuysen E, Vanderstichele A, Vergote I, Walsh CS, Webb PM, Wentzensen N, Whittemore AS, Wu AH, Ziogas A, Odunsi K, Chang-Claude J, Goode EL, Moysich KB; Australian Ovarian Cancer Study.

Cancer Epidemiol Biomarkers Prev. 2017 Mar;26(3):420-424. doi: 10.1158/1055-9965.EPI-16-0631. Epub 2016 Sep 27.

8.

Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the uterine corpus and cervix.

Hasegawa K, Nagao S, Yasuda M, Millan D, Viswanathan AN, Glasspool RM, Devouassoux-Shisheboran M, Covens A, Lorusso D, Kurzeder C, Kim JW, Gladieff L, Bryce J, Friedlander M, Fujiwara K.

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S90-5. doi: 10.1097/IGC.0000000000000297. Review.

PMID:
25341588
9.

Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian and primary peritoneal low-grade serous carcinomas.

Gourley C, Farley J, Provencher DM, Pignata S, Mileshkin L, Harter P, Maenpaa J, Kim JW, Pujaide-Lauraine E, Glasspool RM, Ray-Coquard I, Gershenson D.

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S9-13. doi: 10.1097/IGC.0000000000000257. Review.

PMID:
25341587
10.

Gynecologic Cancer InterGroup (GCIG) consensus review for uterine serous carcinoma.

Sagae S, Susumu N, Viswanathan AN, Aoki D, Backes FJ, Provencher DM, Vaughan M, Creutzberg CL, Kurzeder C, Kristensen G, Lee C, Kurtz JE, Glasspool RM, Small W Jr.

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S83-9. doi: 10.1097/IGC.0000000000000264. Review.

PMID:
25341586
11.

Gynecologic Cancer InterGroup (GCIG) consensus review for mullerian adenosarcoma of the female genital tract.

Friedlander ML, Covens A, Glasspool RM, Hilpert F, Kristensen G, Kwon S, Selle F, Small W, Witteveen E, Russell P.

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S78-82. doi: 10.1097/IGC.0000000000000239. Review.

PMID:
25341585
12.

Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma.

Berton-Rigaud D, Devouassoux-Shisheboran M, Ledermann JA, Leitao MM, Powell MA, Poveda A, Beale P, Glasspool RM, Creutzberg CL, Harter P, Kim JW, Reed NS, Ray-Coquard I.

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S55-60. doi: 10.1097/IGC.0000000000000228. Review.

PMID:
25341582
13.

Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian sex cord stromal tumors.

Ray-Coquard I, Brown J, Harter P, Provencher DM, Fong PC, Maenpaa J, Ledermann JA, Emons G, Rigaud DB, Glasspool RM, Mezzanzanica D, Colombo N.

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S42-7. doi: 10.1097/IGC.0000000000000249. Review.

PMID:
25341579
14.

Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary.

Okamoto A, Glasspool RM, Mabuchi S, Matsumura N, Nomura H, Itamochi H, Takano M, Takano T, Susumu N, Aoki D, Konishi I, Covens A, Ledermann J, Mezzanzanica D, Steer C, Millan D, McNeish IA, Pfisterer J, Kang S, Gladieff L, Bryce J, Oza A.

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S20-5. doi: 10.1097/IGC.0000000000000289. Review. Erratum in: Int J Gynecol Cancer. 2015 May;25(4):721. Mezzazanica, Delia [corrected to Mezzanzanica, Delia].

PMID:
25341576
15.

Gynecologic Cancer InterGroup (GCIG) consensus review for squamous cell carcinoma of the ovary.

Glasspool RM, González Martín A, Millan D, Lorusso D, Åvall-Lundqvist E, Hurteau JA, Davis A, Hilpert F, Kim JW, Alexandre J, Ledermann JA.

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S26-9. doi: 10.1097/IGC.0000000000000209. Review.

PMID:
25126954
16.

A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer.

Glasspool RM, Brown R, Gore ME, Rustin GJ, McNeish IA, Wilson RH, Pledge S, Paul J, Mackean M, Hall GD, Gabra H, Halford SE, Walker J, Appleton K, Ullah R, Kaye S; Scottish Gynaecological Trials Group.

Br J Cancer. 2014 Apr 15;110(8):1923-9. doi: 10.1038/bjc.2014.116. Epub 2014 Mar 18.

17.

Concerning the feasibility of obtaining biopsies for research in relapsed ovarian cancer.

Roxburgh P, Cowell GW, Glasspool RM.

Int J Gynecol Cancer. 2014 Jan;24(1):2-3. doi: 10.1097/IGC.0000000000000060. No abstract available.

PMID:
24356410
18.

Clear cell carcinoma of ovary and uterus.

Glasspool RM, McNeish IA.

Curr Oncol Rep. 2013 Dec;15(6):566-72. doi: 10.1007/s11912-013-0346-0. Review.

PMID:
24114188
19.

Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31.

Permuth-Wey J, Lawrenson K, Shen HC, Velkova A, Tyrer JP, Chen Z, Lin HY, Chen YA, Tsai YY, Qu X, Ramus SJ, Karevan R, Lee J, Lee N, Larson MC, Aben KK, Anton-Culver H, Antonenkova N, Antoniou AC, Armasu SM; Australian Cancer Study; Australian Ovarian Cancer Study, Bacot F, Baglietto L, Bandera EV, Barnholtz-Sloan J, Beckmann MW, Birrer MJ, Bloom G, Bogdanova N, Brinton LA, Brooks-Wilson A, Brown R, Butzow R, Cai Q, Campbell I, Chang-Claude J, Chanock S, Chenevix-Trench G, Cheng JQ, Cicek MS, Coetzee GA; Consortium of Investigators of Modifiers of BRCA1/2, Cook LS, Couch FJ, Cramer DW, Cunningham JM, Dansonka-Mieszkowska A, Despierre E, Doherty JA, Dörk T, du Bois A, Dürst M, Easton DF, Eccles D, Edwards R, Ekici AB, Fasching PA, Fenstermacher DA, Flanagan JM, Garcia-Closas M, Gentry-Maharaj A, Giles GG, Glasspool RM, Gonzalez-Bosquet J, Goodman MT, Gore M, Górski B, Gronwald J, Hall P, Halle MK, Harter P, Heitz F, Hillemanns P, Hoatlin M, Høgdall CK, Høgdall E, Hosono S, Jakubowska A, Jensen A, Jim H, Kalli KR, Karlan BY, Kaye SB, Kelemen LE, Kiemeney LA, Kikkawa F, Konecny GE, Krakstad C, Kjaer SK, Kupryjanczyk J, Lambrechts D, Lambrechts S, Lancaster JM, Le ND, Leminen A, Levine DA, Liang D, Lim BK, Lin J, Lissowska J, Lu KH, Lubiński J, Lurie G, Massuger LF, Matsuo K, McGuire V, McLaughlin JR, Menon U, Modugno F, Moysich KB, Nakanishi T, Narod SA, Nedergaard L, Ness RB, Nevanlinna H, Nickels S, Noushmehr H, Odunsi K, Olson SH, Orlow I, Paul J, Pearce CL, Pejovic T, Pelttari LM, Pike MC, Poole EM, Raska P, Renner SP, Risch HA, Rodriguez-Rodriguez L, Rossing MA, Rudolph A, Runnebaum IB, Rzepecka IK, Salvesen HB, Schwaab I, Severi G, Shridhar V, Shu XO, Shvetsov YB, Sieh W, Song H, Southey MC, Spiewankiewicz B, Stram D, Sutphen R, Teo SH, Terry KL, Tessier DC, Thompson PJ, Tworoger SS, van Altena AM, Vergote I, Vierkant RA, Vincent D, Vitonis AF, Wang-Gohrke S, Palmieri Weber R, Wentzensen N, Whittemore AS, Wik E, Wilkens LR, Winterhoff B, Woo YL, Wu AH, Xiang YB, Yang HP, Zheng W, Ziogas A, Zulkifli F, Phelan CM, Iversen E, Schildkraut JM, Berchuck A, Fridley BL, Goode EL, Pharoah PD, Monteiro AN, Sellers TA, Gayther SA.

Nat Commun. 2013;4:1627. doi: 10.1038/ncomms2613.

20.

Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial.

Barrett SV, Paul J, Hay A, Vasey PA, Kaye SB, Glasspool RM; Scottish Gynaecological Cancer Trials Group.

Ann Oncol. 2008 May;19(5):898-902. doi: 10.1093/annonc/mdm606. Epub 2008 Feb 13.

PMID:
18272913
21.

Epigenetics as a mechanism driving polygenic clinical drug resistance.

Glasspool RM, Teodoridis JM, Brown R.

Br J Cancer. 2006 Apr 24;94(8):1087-92. Review.

22.
24.

Telomerase-directed molecular therapeutics.

Keith WN, Bilsland A, Evans TR, Glasspool RM.

Expert Rev Mol Med. 2002 Apr 22;4(10):1-25. doi: 10.1017/S1462399402004507. Review.

PMID:
14987378
25.

Matrix metalloproteinase inhibitors: past lessons and future prospects in breast cancer.

Glasspool RM, Twelves CJ.

Breast. 2001 Oct;10(5):368-78.

PMID:
14965609
26.

Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954.

Plumb JA, Bilsland A, Kakani R, Zhao J, Glasspool RM, Knox RJ, Evans TR, Keith WN.

Oncogene. 2001 Nov 22;20(53):7797-803.

27.

Telomerase and cancer: time to move from a promising target to a clinical reality.

Keith WN, Jeffry Evans TR, Glasspool RM.

J Pathol. 2001 Nov;195(4):404-14. Review.

PMID:
11745671
28.

Clinical significance of transient hyperthyroidism in the course of non-Hodgkin's lymphoma.

Glasspool RM, Vasey PA, Peden N.

Clin Oncol (R Coll Radiol). 2001;13(4):309-10. No abstract available.

PMID:
11554634
29.

Activation of telomerase rna gene promoter activity by NF-Y, Sp1, and the retinoblastoma protein and repression by Sp3.

Zhao JQ, Glasspool RM, Hoare SF, Bilsland A, Szatmari I, Keith WN.

Neoplasia. 2000 Nov-Dec;2(6):531-9.

30.

Clinical imaging of cancer metastasis.

Glasspool RM, Evans TR.

Eur J Cancer. 2000 Aug;36(13 Spec No):1661-70. Review.

PMID:
10959052

Supplemental Content

Loading ...
Support Center